ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,084.61
-0.26%
Dow Jones
42,840.26
1.18%
Gold vs US Dollar
2,623.175
0.00%
Brent Oil
72.72
0.00%
Bitcoin
97,387.34
-0.38%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Valneva Se (0OB3)

  7. Valneva Se (0OB3) News

Valneva (0OB3)

Valneva Se
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0OB3
DateTimeSourceHeadlineSymbolCompany
19/12/202407:00UK RegulatoryValneva accroît l’accessibilité de son vaccin contre le chikungunya en Asie grâce à une collaboration avec le Serum Institute of IndiaLSE:0OB3Valneva Se
19/12/202407:00UK RegulatoryValneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of IndiaLSE:0OB3Valneva Se
05/12/202406:30UK RegulatoryVALNEVA - Declaration of shares and voting rights: November 30, 2024LSE:0OB3Valneva Se
05/12/202406:30UK RegulatoryDéclaration d'actions et de droits de vote de la société Valneva SE - novembre 2024LSE:0OB3Valneva Se
04/12/202406:00UK RegulatoryValneva annonce la publication dans le British Medical Journal d’un article sur l’impact sanitaire et économique mondial du chikungunyaLSE:0OB3Valneva Se
04/12/202406:00UK RegulatoryValneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical JournalLSE:0OB3Valneva Se
03/12/202406:00UK RegulatoryValneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®LSE:0OB3Valneva Se
03/12/202406:00UK RegulatoryValneva annonce des données positives sur la persistance des anticorps à trois ans pour son vaccin à dose unique contre le chikungunya, IXCHIQ®LSE:0OB3Valneva Se
26/11/202416:45UK RegulatoryValneva soumet à la FDA une demande d’extension d’indication pour son vaccin contre le chikungunya IXCHIQ®LSE:0OB3Valneva Se
26/11/202416:45UK RegulatoryValneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDALSE:0OB3Valneva Se
13/11/202416:45UK RegulatoryValneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2LSE:0OB3Valneva Se
13/11/202416:45UK RegulatoryValneva et LimmaTech annoncent la vaccination du premier participant à l’essai d’infection contrôlée de Phase 2b du candidat vaccin tétravalent contre la shigellose S4V2LSE:0OB3Valneva Se
12/11/202406:00UK RegulatoryValneva fera des présentations et rencontrera les investisseurs lors de conférences aux États-Unis et en EuropeLSE:0OB3Valneva Se
12/11/202406:00UK RegulatoryValneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare ConferencesLSE:0OB3Valneva Se
07/11/202406:00UK RegulatoryValneva publie ses résultats financiers pour les neuf premiers mois de l’exercice 2024 et fait un point sur ses activitésLSE:0OB3Valneva Se
07/11/202406:00UK RegulatoryValneva Reports Nine-Month 2024 Financial Results and Provides Corporate UpdatesLSE:0OB3Valneva Se
06/11/202407:30UK RegulatoryVALNEVA - Declaration of shares and voting rights: October 31, 2024LSE:0OB3Valneva Se
06/11/202407:30UK RegulatoryVALNEVA - Déclaration d’actions et de droits de vote : 31 octobre 2024LSE:0OB3Valneva Se
21/10/202415:45UK RegulatoryValneva effectuera des présentations sur le chikungunya lors de différentes conférences scientifiques de premier planLSE:0OB3Valneva Se
21/10/202415:45UK RegulatoryValneva to Present on Chikungunya at Several Leading Scientific ConferencesLSE:0OB3Valneva Se
16/10/202415:45UK RegulatoryValneva and LimmaTech reçoivent le statut « Fast Track » de la FDA pour leur candidat vaccin tétravalent contre la Shigellose S4VLSE:0OB3Valneva Se
16/10/202415:45UK RegulatoryValneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4VLSE:0OB3Valneva Se
10/10/202405:00UK RegulatoryValneva Hosts Investor Day in New York CityLSE:0OB3Valneva Se
10/10/202405:00UK RegulatoryValneva organise une journée investisseurs aujourd’hui à New YorkLSE:0OB3Valneva Se
04/10/202405:30UK RegulatoryValneva SE - Déclaration d’actions et de droits de vote - 30 septembre 2024LSE:0OB3Valneva Se
04/10/202405:30UK RegulatoryValneva SE - Declaration of shares and voting rights - September 30, 2024LSE:0OB3Valneva Se
03/10/202405:00UK RegulatoryValneva organise une journée investisseurs à New York le 10 octobre 2024LSE:0OB3Valneva Se
03/10/202405:00UK RegulatoryValneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ETLSE:0OB3Valneva Se
18/09/202405:00UK RegulatoryValneva soumet des demandes d’élargissement de l’indication de son vaccin contre le chikungunya IXCHIQ® à l’EMA et Santé CanadaLSE:0OB3Valneva Se
18/09/202405:00UK RegulatoryValneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health CanadaLSE:0OB3Valneva Se
 Showing the most relevant articles for your search:LSE:0OB3

Your Recent History

LSE
AAZ
Anglo Asian Mining
LSE
SYME
Supply@me Capital
LSE
VAST
Vast Resources
LSE
POS
Plexus
LSE
PANR
Pantheon Resources
LSE
ITV
Itv
LSE
PXC
Phoenix Copper
LSE
IMB
Imperial Brands
LSE
SRSP
Sirius Petroleum
LSE
BOO
Boohoo
LSE
UKOG
Uk Oil & Gas
LSE
SNG
Synairgen
LSE
GBP
Global Petroleum
LSE
MARS
Marston's
LSE
BARC
Barclays
LSE
QBT
Quantum Blockchain Techn...
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads